Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?

Solmaz F., Gundogdu E., AKDUMAN D., Haksever M., Dikici O., Unal F.

TOXICOLOGY REPORTS, cilt.3, ss.401-404, 2016 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.toxrep.2016.03.010
  • Dergi Adı: TOXICOLOGY REPORTS
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.401-404
  • Bursa Uludağ Üniversitesi Adresli: Hayır

Özet

Introduction: Aminoglycosides (AGs) have been widely used for potential life-threatening bacterial infections. Although AGs are well known for their ototoxic side effects, some AGs such as amikacin are considered less harmful to auditory functions; thus, auditory monitoring is mostly neglected during treatment with these drugs.